Search Result for "*:*"
provider

Rajat Garg, MD Advanced Interventional Gastroenterology, Pancreas and Liver

Research & Publications

Aphase1a/ 1bfirst-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.